The Tissue and Blood Bank Core for the Lung Cancer SPORE will serve as a shared resource for the main Research Projects and for the Career Development and Developmental Research Programs. The Core will collect, process, store and distribute tissue and body fluid specimens from patients diagnosed with lung cancer or with suspected lung cancer, and from subjects who are members of the PLuSS cohort and the PLuSS High-Risk Sub-Cohort. Triage and distribution of all specimens will be prioritized according to a plan established with all SPORE investigators, and approved by the Tissue and Blood Bank Core Pathologists. The Core will procure and triage fresh human lung tissue, including tumor, adjacent uninvolved, and normal tissues distal from the tumor, and biopsies of the airway, from lung cancer patients undergoing resections or bronchoscopies, as well as individuals undergoing these procedures for reasons other than lung cancer. After triage under sterile conditions, tissues designated by the Core Pathologist as normal or abnormal will be either immediately distributed to investigators as needed for experimentation or stored for future use. Lymphocytes, serum, and plasma will be separated from other blood components and used immediately or stored for future analysis. Sputum will also be collected and processed. Tissues will also be formalin fixed for paraffin embedding. Tumor blocks from patients enrolled in clinical trials will be obtained and stored by the Core. Paraffin embedded specimens will be either sectioned for use in staining protocols or used for the preparation of tissue microarrays (TMAs). The Core will also carry out Kras and EGFR mutation analyses on microdissected tumor specimens and will utilize tumor tissue sections for EGFR amplification analyses by fluorescence in situ hybridization (FISH). The Core will also carry out routine and special pathology such as immunohistochemistry, morphometry, digital imaging and photography. Modifications will be made as necessary to meet any changes in SPORE research goals. All tissues will be collected through IRB approved protocols on which Tissue and Blood Bank Core pathologists will be co-investigators. The Tissue Core will take advantage of infrastructure at UPCI for procurement of tissue, but will not duplicate it.

Public Health Relevance

In order to carry out translational studies, it is necessary to utilize biospecimens from lung cancer patients and individuals at risk for lung cancer to analyze genetic predisposition, biomarkers of presence of lung cancer, and biomarkers that predict disease risk, disease outcome or response to therapy. The Tissue and Blood Bank Core will provide essential pathology and banking services to carry out translational studies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA090440-12
Application #
8555310
Study Section
Special Emphasis Panel (ZCA1-RPRB-7 (M1))
Project Start
2001-06-01
Project End
2016-08-31
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
12
Fiscal Year
2012
Total Cost
$155,346
Indirect Cost
$52,807
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Tarhini, Ahmad A; Rafique, Imran; Floros, Theofanis et al. (2017) Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer. Cancer 123:2936-2944
Sun, Fan; Xiao, Gutian; Qu, Zhaoxia (2017) Isolation of Murine Alveolar Type II Epithelial Cells. Bio Protoc 7:
Chatterjee, Suman; Huang, Eric H-B; Christie, Ian et al. (2017) Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERK-p90RSK-mTOR Signaling Network. Mol Cancer Ther 16:793-804
Moiseeva, Tatiana; Hood, Brian; Schamus, Sandy et al. (2017) ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1. Nat Commun 8:1392
Vendetti, Frank P; Leibowitz, Brian J; Barnes, Jennifer et al. (2017) Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. Sci Rep 7:41892
Chatterjee, Suman; Huang, Eric H-B; Christie, Ian et al. (2017) Reactivation of the p90RSK-CDC25C Pathway Leads to Bypass of the Ganetespib-Induced G2-M Arrest and Mediates Acquired Resistance to Ganetespib in KRAS-Mutant NSCLC. Mol Cancer Ther 16:1658-1668
Dandachi, Nadine; Kelly, Neil J; Wood, John P et al. (2017) Macrophage Elastase Induces TRAIL-mediated Tumor Cell Death through Its Carboxy-Terminal Domain. Am J Respir Crit Care Med 196:353-363
Sun, Fan; Xiao, Gutian; Qu, Zhaoxia (2017) Murine Bronchoalveolar Lavage. Bio Protoc 7:
Yochum, Zachary A; Cades, Jessica; Mazzacurati, Lucia et al. (2017) A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. Mol Cancer Res 15:1764-1776
Zhou, Jingjiao; Qu, Zhaoxia; Sun, Fan et al. (2017) Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation. Cancer Immunol Res 5:257-268

Showing the most recent 10 out of 183 publications